Anuh Pharma Ltd. released its Q4 FY2023-24 results, showing a 15.85% increase in revenue to ₹1,900 crore. However, net profit declined by 18.62% to ₹125 crore. The company's EBITDA margin contracted to 10.48%. Despite Q4 challenges, annual performance for FY2024 was strong with a 23.52% revenue growth and 66.02% increase in net profit. The board recommended a dividend of ₹1.50 per equity share.